Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novartis AG (NVS) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance

Novartis AGTrade
TAKE-TWO INTERACTIVE SOFTWARE, INC Common StockTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Novartis AG trades at $139.46 (market cap $262.64B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $211.55 (market cap $39.88B). The key difference: Novartis AG is far larger — about 6.6× TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock's market cap, and Novartis AG pays a 3.44% dividend while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock pays none. Which is the better fit depends on your goals.

NVSTTWO
Market Cap
$262.64B$39.88B
Sector
HealthMedia
52-Week High
$168.62$262.29
52-Week Low
$121.80$189.69
Enterprise Value
$303.97B$41.00B
Dividend Yield
3.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock

Take-Two Interactive trades at $213.29, down 0.65% amid bearish technical signals despite strong analyst support. The stock shows negative profitability with a -4.79% net margin and -$4.48B net loss for 2025, though recent earnings beats and GTA 6's November launch anticipation provide catalysts. Cash flow improved to $457M net inflow in 2025 from prior deficits, while debt-to-asset ratio rose to 39.87%.

Outlook hinges on GTA 6's execution, with 79% analyst buy ratings and $302.60 price target suggesting 42% upside. Risks include high valuation multiples (P/S 5.91, EV/EBITDA 32.78) and reliance on single-title success. Near-term volatility may persist pending Q3 earnings and preorder trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS

About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock

Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.

Read more on TTWO